RESUMEN

Investigating the dynamics of structural elements in functional RNAs is important to better understand their mechanism and for engineering RNAs with novel functions. Previously, we performed rational engineering studies with the Varkud satellite (VS) ribozyme and switched its specificity toward non-natural hairpin substrates through modification of a critical kissing-loop interaction (KLI). We identified functional VS ribozyme variants with surrogate KLIs (ribosomal RNA L88/L22 and human immunodeficiency virus-1 TAR/TAR*), but they displayed ∼100-fold lower cleavage activity. Here, we characterized the dynamics of KLIs to correlate dynamic properties with function and improve the activity of designer ribozymes. Using temperature replica exchange molecular dynamics, we determined that the natural KLI in the VS ribozyme supports conformational sampling of its closed and active state, whereas the surrogate KLIs display more restricted motions. Based on in vitro selection, the cleavage activity of a VS ribozyme variant with the TAR/TAR* KLI could be markedly improved by partly destabilizing the KLI but increasing conformation sampling. We formulated a mechanistic model for substrate binding in which the KLI dynamics contribute to formation of the active site. Our model supports the modular nature of RNA in which subdomain structure and dynamics contribute to define the thermodynamics and kinetics relevant to RNA function.

Asunto(s)

Endorribonucleasas/química , VIH-1/química , ARN Catalítico/química , Proteínas de Unión al ARN/química , ARN/química , Sitios de Unión , Endorribonucleasas/genética , Genes de ARNr/genética , VIH-1/genética , Modelos Moleculares , Conformación de Ácido Nucleico , ARN/genética , ARN Catalítico/genética , ARN no Traducido/química , ARN no Traducido/genética , Proteínas de Unión al ARN/genética , Termodinámica

RESUMEN

The Neurospora VS ribozyme is a catalytic RNA that has the unique ability to specifically recognize and cleave a stem-loop substrate through formation of a highly stable kissing-loop interaction (KLI). In order to explore the engineering potential of the VS ribozyme to cleave alternate substrates, we substituted the wild-type KLI by other known KLIs using an innovative engineering method that combines rational and combinatorial approaches. A bioinformatic search of the protein data bank was initially performed to identify KLIs that are structurally similar to the one found in the VS ribozyme. Next, substrate/ribozyme (S/R) pairs that incorporate these alternative KLIs were kinetically and structurally characterized. Interestingly, several of the resulting S/R pairs allowed substrate cleavage with substantial catalytic efficiency, although with reduced activity compared to the reference S/R pair. Overall, this study describes an innovative approach for RNA engineering and establishes that the KLI of the trans VS ribozyme can be adapted to cleave other folded RNA substrates.

Asunto(s)

Endorribonucleasas/metabolismo , Neurospora/enzimología , Conformación de Ácido Nucleico , Ingeniería de Proteínas , ARN Catalítico/metabolismo , Secuencia de Bases , Biocatálisis , Biología Computacional , Cristalografía por Rayos X , Bases de Datos de Proteínas , Endorribonucleasas/química , Estabilidad de Enzimas , Cinética , Espectroscopía de Resonancia Magnética , Modelos Moleculares , ARN Catalítico/química , Especificidad por Sustrato , Termodinámica

RESUMEN

Important structural differences imply that human and mouse mast cell chymases may differ with respect to their enzymatic properties. We compared in this study the catalytic efficiencies of recombinant human chymase (rCMA1) and its functional murine homologue recombinant mouse mast cell protease-4 (rmMCP-4) toward a fluorogenic chymase substrate (Suc-Ala-Ala-Pro-Phe-7-amino-4-methylcoumarin (AMC) and by their ability to convert Big-endothelin (ET)-1 into ET-1 (1-31) using a LC/MS/MS system. Activities toward a fluorogenic substrate (Suc-Leu-Leu-Val-Tyr-AMC) and Big ET-1 were also measured in extracts from mouse peritoneal mast cells, LUVA human mast cell-like cells and human aortas. The specificity of these activities was assessed with the chymase inhibitor TY-51469 (2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfonamido-3-methanesulfonyl-phenyl]thiazole-4-carboxylic acid). For similar affinities, rmMCP-4 showed a higher activity toward the fluorogenic substrate and a higher ability to process Big ET-1 as compared to recombinant CMA1 (chymase activity (kcat/KM in µM(-1)s(-1)): 2.29 × 10(-4)vs. 6.41 × 10(-6); ET-1 (1-31) production: 2.19 × 10(-3)vs. 6.57 × 10(-5)), and both of these activities of mouse and human chymase were sensitive to TY-51469. Furthermore, extracts from mouse peritoneal mast cells, LUVA cells and human aorta homogenates contained processing activities toward the fluorogenic chymase substrate as well as Big ET-1, all of which were sensitive to TY-51469. Finally, the pressor responses to Big ET-1 but not to ET-1 were significantly reduced in conscious and free moving mMCP-4 KO mice when compared to wild type congeners. Our results suggest that both mouse and human chymases have potent ET-1 (1-31)-producing abilities, with the murine isoform being more efficient.

Asunto(s)

Quimasas/antagonistas & inhibidores , Endotelina-1/análogos & derivados , Inhibidores Enzimáticos/farmacología , Fragmentos de Péptidos/síntesis química , Serina Endopeptidasas/metabolismo , Animales , Cromatografía Liquida , Quimasas/metabolismo , Endotelina-1/síntesis química , Humanos , Ratones , Ratones Endogámicos C57BL , Serina Endopeptidasas/genética , Espectrometría de Masas en Tándem

RESUMEN

The serine protease chymase has been reported to generate intracardiac angiotensin-II (Ang-II) from Ang-I as well as an intermediate precursor of endothelin-1 (ET-1), ET-1 (1-31) from Big-ET-1. Although humans possess only one chymase, several murine isoforms are documented, each with its own specific catalytic activity. Among these, mouse mast cell protease 4 (mMCP-4) is the isoform most similar to the human chymase for its activity. The aim of this study was to characterize the capacity of mMCP-4 to convert Big-ET-1 into its bioactive metabolite, ET-1, in vitro and in vivo in the mouse model. Basal mean arterial pressure did not differ between wild-type (WT) and mMCP-4(-/-) mice. Systemic administration of Big-ET-1 triggered pressor responses and increased blood levels of immunoreactive (IR) ET-1 (1-31) and ET-1 that were reduced by more than 50% in mMCP-4 knockout (-/-) mice compared with WT controls. Residual responses to Big-ET-1 in mMCP-4(-/-) mice were insensitive to the enkephalinase/neutral endopeptidase inhibitor thiorphan and the specific chymase inhibitor TY-51469 {2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfonamido-3-methanesulfonylphenyl]thiazole-4-carboxylic acid}. Soluble fractions from the lungs, left cardiac ventricle, aorta, and kidneys of WT but not mMCP-4(-/-) mice generated ET-1 (1-31) from exogenous Big-ET-1 in a TY-51469-sensitive fashion as detected by high-performance liquid chromatography/ matrix-assisted laser desorption/ionization-mass spectrometry. Finally, pulmonary endogenous levels of IR-ET-1 were reduced by more than 40% in tissues derived from mMCP-4(-/-) mice compared with WT mice. Our results show that mMCP-4 plays a pivotal role in the dynamic conversion of systemic Big-ET-1 to ET-1 in the mouse model.

Asunto(s)

Aorta/enzimología , Endotelina-1/metabolismo , Ventrículos Cardíacos/enzimología , Serina Endopeptidasas/metabolismo , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Carboxipeptidasas A/biosíntesis , Carboxipeptidasas A/genética , Carboxipeptidasas A/metabolismo , Resistencia a Medicamentos , Endotelina-1/análogos & derivados , Endotelina-1/sangre , Regulación Enzimológica de la Expresión Génica , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Hemodinámica/efectos de los fármacos , Isoenzimas/biosíntesis , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Especificidad de Órganos , Fragmentos de Péptidos/sangre , Fragmentos de Péptidos/metabolismo , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Proteolisis/efectos de los fármacos , ARN Mensajero/metabolismo , Serina Endopeptidasas/química , Serina Endopeptidasas/genética , Inhibidores de Serina Proteinasa/farmacología , Sulfonamidas/farmacología , Tiofenos/farmacología , Tiorfan/farmacología

RESUMEN

We recently identified a novel human B2 receptor (B2R) agonist [Hyp(3),Thi(5),(N)Chg(7),Thi(8)]-bradykinin (NG291) with greater in vitro and in vivo potency and duration of action than natural bradykinin (BK). Here, we further examined its stability and selectivity toward B2R. The hypotensive, antithrombotic, and profibrinolytic functions of NG291 relative to BK and its analogue ([Hyp(3),Thi(5),(4-Me)Tyr(8)(ΨCH(2)NH)Arg(9)]-BK) (RMP-7) were also tested. Contraction assays using isolated mouse stomachs (containing kinin B1R, B2R, and kininase I- and II-like activities) showed that NG291 is a more potent contractant than BK and is inhibited by HOE-140 (B2R antagonist) but unaffected by R954 (B1R antagonist), whereas both decreased the potency of BK. In stomach tissues from B2R knockout mice, BK maintained its activity via B1R, whereas NG291 had no contractile effect, indicating that it was selective for B2R. Unlike BK, NG291 was not degraded by rabbit lung ACE. Comparing intravenously administered BK and NG291 revealed that NG291 exhibited more potent and prolonged hypotensive action and greater antithrombotic and profibrinolytic activities. These effects were of comparable magnitude to RMP-7 and were absent in B2R knockout mice. We concluded that NG291 is a novel biostable B2R-selective agonist that may prove suitable for investigating the (pre)clinical cardioprotective efficacy of B2R activation.

Asunto(s)

Contracción Muscular/efectos de los fármacos , Péptidos/farmacología , Receptor de Bradiquinina B2/agonistas , Animales , Técnicas de Química Sintética , Fibrinolíticos/farmacología , Ratones , Ratones Noqueados , Péptidos/química , Peptidomiméticos , Unión Proteica/efectos de los fármacos

RESUMEN

Compensatory mutations in RNA are generally regarded as those that maintain base pairing, and their identification forms the basis of phylogenetic predictions of RNA secondary structure. However, other types of compensatory mutations can provide higher-order structural and evolutionary information. Here, we present a helix-length compensation study for investigating structure-function relationships in RNA. The approach is demonstrated for stem-loop I and stem-loop V of the Neurospora VS ribozyme, which form a kissing-loop interaction important for substrate recognition. To rapidly characterize the substrate specificity (k(cat)/K(M)) of several substrate/ribozyme pairs, a procedure was established for simultaneous kinetic characterization of multiple substrates. Several active substrate/ribozyme pairs were identified, indicating the presence of limited substrate promiscuity for stem Ib variants and helix-length compensation between stems Ib and V. 3D models of the I/V interaction were generated that are compatible with the kinetic data. These models further illustrate the adaptability of the VS ribozyme architecture for substrate cleavage and provide global structural information on the I/V kissing-loop interaction. By exploring higher-order compensatory mutations in RNA our approach brings a deeper understanding of the adaptability of RNA structure, while opening new avenues for RNA research.

Asunto(s)

Endorribonucleasas/química , ARN Catalítico/química , Endorribonucleasas/metabolismo , Cinética , Modelos Moleculares , Mutación , Conformación de Ácido Nucleico , ARN Catalítico/metabolismo , Relación Estructura-Actividad , Especificidad por Sustrato

RESUMEN

As for other peptides such as bradykinin, neurokinins and angiotensins, peptide antagonists for endothelin-1 (ET-1) have been early on developed towards the pharmacological characterization of both ET(A) and ET(B) receptors. Interestingly, unlike the previously mentioned three peptides, receptors for ET-1 were cloned and purified prior to the report of ET(A)and ET(B)receptor antagonists such as BQ-123 and BQ-788. The availability of such pharmacological tools and the use of molecular approaches have certainly fast-tracked the development of non-peptide ET receptor antagonists for clinical applications. Albeit rapid degradation by gastric enzymes and short half-life in plasma of peptide receptor antagonists limit their use in clinical settings, those molecules have been of importance in the identification of mediators and modulators of ET-1 induced properties in vitro and in vivo, as described further in this review. Peptide antagonists acting selectively or, with equivalent affinities against ET(A)and ET(B)receptors were reported prior to the advent of clinically relevant non-peptide blockers such as Bosentan. Confounding mechanisms involving, for example, the endogenous modulators nitric oxide and prostacyclin as well as allosteric interactions between ET receptor types, have also been clarified with the use of peptide antagonists for endothelins. Finally, peptide antagonists were also used to identify the precise pharmacology of ET-1 precursors such as big-endothelin-1 and ET-1 (1-31). The present review will thus attempt to summarize the knowledge to date and future perspectives related to use of peptide antagonists targeting endothelin receptors in physiological and pathological settings.

Asunto(s)

Antagonistas de los Receptores de la Endotelina A , Antagonistas de los Receptores de la Endotelina B , Péptidos/farmacología , Animales , Sistemas de Liberación de Medicamentos , Diseño de Fármacos , Endotelina-1/metabolismo , Semivida , Humanos , Péptidos/farmacocinética , Receptor de Endotelina A/metabolismo , Receptor de Endotelina B/metabolismo

RESUMEN

We hypothesized that constitutive endothelial NO synthase (eNOS) and inducible NO synthase (iNOS) have opposite effects on the regulation of endothelin and its receptors. We therefore sought to determine whether deletions of iNOS or eNOS genes in mice modulate pressor responses to endothelin and the expression of ETA and ETB receptors in a similar fashion. Despite unchanged baseline hemodynamic parameters, anesthetized iNOS-/- mice displayed reduced pressor responses to endothelin-1, but not to that of IRL-1620, a selective ETB agonist. Protein content of cardiac ETA receptors was reduced in iNOS-/- mice compared with wild-type mice, but that of ETB receptors was unchanged. Anesthetized eNOS-/- mice presented a hypertensive state, accompanied by an enhanced pressor response to intravenous endothelin-1, whereas the pressor response to IRL-1620 was reduced. Protein levels were also found to be increased for ETA receptors, but reduced for ETB receptors, in cardiac tissues of eNOS-/- mice. In conscious animals, both strains responded equally to the hypotensive effect of an ETA antagonist, ABT-627, whereas orally administered A-192621, an ETB antagonist, increased MAP to a greater extent in eNOS-/- than in wild-type mice. Furthermore, significant levels of immunoreactive endothelin were found in mesenteric arteries in eNOS-/- but not in iNOS-/- or wild-type congeners. Our study shows that repression of iNOS or eNOS has differential effects on endothelin-1 and its receptors. We have also shown that the heart is the main organ in which iNOS or eNOS repression induces important alterations in protein content of endothelin receptors in adult mice.

Asunto(s)

Endotelina-1/fisiología , Óxido Nítrico Sintasa de Tipo III/genética , Óxido Nítrico Sintasa de Tipo II/genética , Transducción de Señal/fisiología , Animales , Cartilla de ADN , ADN Complementario/biosíntesis , ADN Complementario/genética , Antagonistas de los Receptores de la Endotelina A , Antagonistas de los Receptores de la Endotelina B , Endotelina-1/genética , Endotelina-1/farmacología , Endotelinas/farmacología , Ratones , Ratones Noqueados , Nitratos/metabolismo , Óxido Nítrico Sintasa de Tipo II/fisiología , Óxido Nítrico Sintasa de Tipo III/fisiología , Nitritos/metabolismo , Fragmentos de Péptidos/farmacología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptor de Endotelina A/agonistas , Receptor de Endotelina B/agonistas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/genética , Superóxidos/metabolismo , Telemetría

RESUMEN

Substrate recognition by the VS ribozyme involves a magnesium-dependent loop/loop interaction between the SLI substrate and the SLV hairpin from the catalytic domain. Recent NMR studies of SLV demonstrated that magnesium ions stabilize a U-turn loop structure and trigger a conformational change for the extruded loop residue U700, suggesting a role for U700 in SLI recognition. Here, we kinetically characterized VS ribozyme mutants to evaluate the contribution of U700 and other SLV loop residues to SLI recognition. To help interpret the kinetic data, we structurally characterized the SLV mutants by NMR spectroscopy and generated a three-dimensional model of the SLI/SLV complex by homology modeling with MC-Sym. We demonstrated that the mutation of U700 by A, C, or G does not significantly affect ribozyme activity, whereas deletion of U700 dramatically impairs this activity. The U700 backbone is likely important for SLI recognition, but does not appear to be required for either the structural integrity of the SLV loop or for direct interactions with SLI. Thus, deletion of U700 may affect other aspects of SLI recognition, such as magnesium ion binding and SLV loop dynamics. As part of our NMR studies, we developed a convenient assay based on detection of unusual (31)P and (15)N N7 chemical shifts to probe the formation of U-turn structures in RNAs. Our model of the SLI/SLV complex, which is compatible with biochemical data, leads us to propose novel interactions at the loop I/loop V interface.

Asunto(s)

Endorribonucleasas/metabolismo , Neurospora/metabolismo , ARN Catalítico/metabolismo , ARN de Hongos/metabolismo , Secuencia de Bases , Endorribonucleasas/química , Endorribonucleasas/genética , Cinética , Modelos Moleculares , Datos de Secuencia Molecular , Mutación , Neurospora/genética , Resonancia Magnética Nuclear Biomolecular , Conformación de Ácido Nucleico , ARN Catalítico/química , ARN Catalítico/genética , ARN de Hongos/química , ARN de Hongos/genética , Especificidad por Sustrato

RESUMEN

The precursor of endothelin-1, big endothelin-1, can be hydrolyzed by chymase to generate endothelin-1 (1-31) in vitro. In the present study, we explored the processes involved in the production of endothelin-1 (1-31) as well as its pharmacodynamic characteristics in the rabbit in vivo. Endothelin-1 (1-31) (1 nmol/kg, injected into the left cardiac ventricle) induced a monophasic increase of mean arterial blood pressure similarly to big endothelin-1 (1-38), whereas endothelin-1 induces a biphasic response. Phosphoramidon, a dual neutral endopeptidase and endothelin-converting enzyme inhibitor, blocked both pressor responses to endothelin-1 (1-31) and big endothelin-1 but not those afforded by endothelin-1. Thiorphan, a neutral endopeptidase inhibitor, markedly inhibited the response to endothelin-1 (1-31) but only weakly reduced that of big endothelin-1. In contrast, CGS 35066, an endothelin-converting enzyme inhibitor, was significantly more efficient against the pressor response to big endothelin-1 than to endothelin-1 (1-31). Furthermore, injection of big endothelin-1 concomitantly with phosphoramidon induced an increase in endothelin-1 (1-31) plasma levels. Finally, intracardiac-administered endothelin-1 (1-31) induced an increase of endothelin-1 plasma levels, which are markedly reduced by phosphoramidon and thiorphan but not by CGS 35066. Our results thus demonstrate that endothelin-1 (1-31) is an alternate intermediate in the production of endothelin-1 after big endothelin-1 administration in the rabbit in vivo.

Asunto(s)

Endotelina-1/análogos & derivados , Endotelina-1/biosíntesis , Endotelina-1/farmacología , Fragmentos de Péptidos/biosíntesis , Animales , Ácido Aspártico Endopeptidasas/antagonistas & inhibidores , Ácido Aspártico Endopeptidasas/metabolismo , Benzofuranos/farmacología , Presión Sanguínea/efectos de los fármacos , Endotelina-1/administración & dosificación , Endotelina-1/antagonistas & inhibidores , Endotelina-1/sangre , Endotelina-1/metabolismo , Enzimas Convertidoras de Endotelina , Femenino , Glicopéptidos/farmacología , Ventrículos Cardíacos , Inyecciones , Masculino , Metaloendopeptidasas/antagonistas & inhibidores , Metaloendopeptidasas/metabolismo , Neprilisina/metabolismo , Organofosfonatos/farmacología , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Inhibidores de Proteasas/farmacología , Conejos , Receptores de Endotelina/metabolismo , Tiorfan/farmacología

RESUMEN

In the vascular system, endothelin (ET) type B (ET(B)) receptors for ET-1 are located on endothelial and on venous and arterial smooth muscle cells. In the present study, we investigated the hemodynamic effects of chronic ET(B) receptor blockade at low and high doses in the Syrian Golden hamster. After 16 days of gavage with A-192621 (0.5 or 30 mg.kg(-1).day(-1)), a selective ET(B) receptor antagonist, hamsters were anesthetized with a mixture of ketamine and xylazine (87 and 13 mg/kg im, respectively), and basal mean arterial blood pressure (MAP) and pressor responses to exogenous ET-1 were evaluated. The lower dose of A-192621 (0.5 mg.kg(-1).day(-1)) did not modify basal MAP, whereas the higher dose (30 mg.kg(-1).day(-1)) increased MAP and plasma ET levels. Radio-telemetry recordings confirmed the increase in MAP induced by the higher dose of A-192621 in conscious hamsters. On the other hand, although the lower dose of A-192621 was devoid of intrinsic pressor effects, it markedly reduced the transient hypotensive phase induced by intravenously injected IRL-1620, a selective ET(B) receptor agonist. Finally, A-192621 (0.5 mg.kg(-1).day(-1)) alone or A-192621 (30 mg.kg(-1).day(-1)) + atrasentan (6 mg.kg(-1).day(-1)), a selective ET(A) receptor antagonist, potentiated the pressor response to exogenous ET-1. Our results suggest that, in the hamster, ET(B) receptors on vascular smooth muscle cells are importantly involved in the clearance of endogenous ET-1, whereas the same receptor type on the endothelium is solely involved in the vasodilatory responses to the pressor peptide. Blockade of endothelial and vascular smooth muscle cell ET(B) receptors triggers a marked potentiation of ET(A)-dependent increases in systemic resistance.

Asunto(s)

Antagonistas de los Receptores de la Endotelina B , Endotelio Vascular/efectos de los fármacos , Hipertensión/inducido químicamente , Hipertensión/metabolismo , Músculo Liso Vascular/efectos de los fármacos , Anestesia , Animales , Atrasentán , Presión Sanguínea/efectos de los fármacos , Estado de Conciencia , Cricetinae , Relación Dosis-Respuesta a Droga , Endotelina-1/antagonistas & inhibidores , Endotelina-1/farmacología , Endotelinas/farmacología , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Masculino , Mesocricetus , Músculo Liso Vascular/citología , Músculo Liso Vascular/metabolismo , Fragmentos de Péptidos/farmacología , Pirrolidinas/farmacología , Receptor de Endotelina A/metabolismo , Receptor de Endotelina B/metabolismo

RESUMEN

BACKGROUND: Cardiovascular diseases remain a major cause of death and disability in the Western world. Among the various approaches adopted to counteract the morbidity associated with these diseases, surgical procedures and cardiac and vascular xenotransplantations or allotransplantations are routinely performed. The suitable vascular graft would be as close as possible to the native and healthy vessel composed exclusively of human components provided by the patient and would adapt to the donor's hemodynamics. We have developed such a tissue-engineered human blood vessel reconstructed with human cells. Because endothelin is the most potent vasopressor known to date, we were interested in investigating the functionality of the endothelinergic system in our reconstructed human blood vessel. METHODS AND RESULTS: Vasoconstriction studies were performed with nonselective and selective agonists and antagonists to demonstrate that ET(A) receptors were present and functional in tissue-engineered human vascular media constructed with the self-assembly method. Reverse-transcriptase polymerase chain reaction studies demonstrated that mRNA of the ET(A) but not the ET(B) receptor was present in these human tissue-engineered blood vessels. Furthermore, we demonstrated that the endothelin-converting enzyme, the main enzyme responsible for the formation of the biologically active endothelin peptides, was present and functional in these same bioengineered vascular media. CONCLUSIONS: Our results suggest that the media component of our tissue-engineered blood vessel has the potential of controlling vascular resistance via the presence of functional endothelin ET(A) receptors and endothelin-converting enzyme.

Asunto(s)

Endotelinas/fisiología , Receptor de Endotelina A/fisiología , Ingeniería de Tejidos , Túnica Media/fisiología , Ácido Aspártico Endopeptidasas/metabolismo , Células Cultivadas/citología , Células Endoteliales/citología , Enzimas Convertidoras de Endotelina , Endotelio Vascular/citología , Humanos , Metaloendopeptidasas/metabolismo , Músculo Liso Vascular/citología , Miocitos del Músculo Liso/citología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptor de Endotelina A/biosíntesis , Receptor de Endotelina A/genética , Receptor de Endotelina B/biosíntesis , Receptor de Endotelina B/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Túnica Media/efectos de los fármacos , Venas Umbilicales/citología , Resistencia Vascular , Vasoconstrictores/farmacología , Vasodilatadores/farmacología

RESUMEN

Apoptosis(programmed cell death) is induced in pulmonary cells and contributes to the pathogenesis of acute lung injury in septic humans. Previous studies have shown that nitric oxide (NO) is an important modulator of apoptosis; however, the functional role of NO derived from inducible NO synthase (iNOS) in sepsis-induced pulmonary apoptosis remains unknown. We measured pulmonary apoptosis in a rat model of Escherichia coli lipopolysaccharide (LPS)-induced sepsis in the absence and presence of the selective iNOS inhibitor 1400W. Four groups were studied 24 h after saline (control) or LPS injection in the absence and presence of 1400W pretreatment. Apoptosis was evaluated using DNA fragmentation, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining, and caspase activation. LPS administration significantly augmented pulmonary cell apoptosis and caspase-3 activity in airway and alveolar epithelial cells. Pretreatment with 1400W significantly enhanced LPS-induced pulmonary apoptosis and increased caspase-3 and -7 activation. The antiapoptotic effect of iNOS was confirmed in iNOS-/- mice, which developed a greater degree of pulmonary apoptosis both under control conditions and in response to LPS compared with wild-type mice. By comparison, genetic deletion of the neuronal NOS had no effect on LPS-induced pulmonary apoptosis. We conclude that NO derived from iNOS plays an important protective role against sepsis-induced pulmonary apoptosis.

Asunto(s)

Apoptosis/fisiología , Enfermedades Pulmonares/metabolismo , Óxido Nítrico Sintasa/metabolismo , Sepsis/metabolismo , Enfermedad Aguda , Amidinas/farmacología , Animales , Apoptosis/efectos de los fármacos , Bencilaminas/farmacología , Caspasas/metabolismo , Inhibidores Enzimáticos/farmacología , Lipopolisacáridos/farmacología , Enfermedades Pulmonares/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo I , Óxido Nítrico Sintasa de Tipo II , Ratas , Ratas Sprague-Dawley , Sepsis/patología

RESUMEN

Nitric oxide (NO) has been shown to be a physiological antagonist of the potent pressor agent endothelin-1, a transcriptional and post-transcriptional repressor of the production of this particular peptide as well as an endogenous modulator of vascular resistance in several animal species as well as in man. The aim of the present study was to assess the hemodynamic properties of endothelin-1 in endothelial NO synthase knockout mice (eNOS (-/-) KO). Ketamine- xylazine anesthetized eNOS (-/-) KO mice show a significantly higher mean arterial pressure (+25.7 +/- 4.3 mmHg, n = 10) than their wild-type congeners (C57BL/6 background). eNOS (-/-) KO mice, when subjected to systemically administered endothelin-1 or the selective endothelin-B agonist IRL-1620 (1 nmol/kg, each), responded by markedly enhanced and reduced pressor responses (systolic, diastolic and mean arterial pressure), respectively, when compared with wild-type mice. Surprisingly, plasma levels of immunoreactive endothelin are not significantly different in endothelial nitric oxide synthase knockout mice and wild-type mice. Our results suggest that chronic repression of endothelial nitric oxide synthase affects in opposite fashion the functionality of endothelin-A and endothelin-B receptor-dependent responses. The increase in mean arterial pressure afforded in endothelial nitric oxide synthase knockout mice does not appear to involve an increase in production of endogenous endothelin in vivo.

Asunto(s)

Presión Sanguínea/efectos de los fármacos , Arterias Carótidas/efectos de los fármacos , Antagonistas de los Receptores de la Endotelina B , Endotelina-1/metabolismo , Endotelinas/farmacología , Óxido Nítrico Sintasa de Tipo II/metabolismo , Fragmentos de Péptidos/farmacología , Vasoconstricción/efectos de los fármacos , Animales , Arterias Carótidas/metabolismo , Endotelina-1/sangre , Frecuencia Cardíaca/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo II/deficiencia , Óxido Nítrico Sintasa de Tipo II/genética , Óxido Nítrico Sintasa de Tipo III , Receptor de Endotelina B/metabolismo , Factores de Tiempo , Resistencia Vascular/efectos de los fármacos

RESUMEN

Knockout (KO) mice models have generated a wealth of new information on the developmental and physiopathological roles of several hormones and their receptors. In these mice, KO of a specific gene can be lethal at embryonic stages or during early adulthood. Furthermore, in conditions of non-lethality, KO mice may compensate for the repression of a particular protein expression. As a result of these two aspects, various phenotypic expressions occur in KO mice models for several peptides and their respective receptors, as well as for the enzymes involved in their processing.

Asunto(s)

Enfermedades Cardiovasculares/genética , Ratones Noqueados/genética , Animales , Humanos , Ratones , Ratones Noqueados/fisiología

RESUMEN

Mice with disruption of the kinin B(2) receptor (B(2)KO mice) are sensitive to salt-rich diets, which causes hypertension. The aim of the study was to assess the role of endothelin-1 (ET-1) and angiotensin-II in hypertensive B(2)KO mice on a salt-rich diet. We also wanted to verify if there is an upregulation of the mRNA expression of the precursors or receptors for these hormones. Two groups of B(2)KO mice (20-25 g) were investigated. The first group received an 8% NaCl diet with 1% NaCl in drinking water (HS) and the second was fed with normal food with tap water (NS). The antagonists tested were the ET(A) receptor antagonist BQ-123 (1 and 5 mg/kg), the ET(B) receptor antagonist BQ-788 (0.25 and 1 mg/kg), the angiotensin receptor type 1 antagonist losartan (10 mg/kg) and the angiotensin-converting enzyme inhibitor captopril (3 mg/kg). These were injected intraperitoneally 30 min prior to blood pressure measurement by the tail-cuff method. We also studied the level of expression of preproET-1, ET-1 receptors, angiotensinogen and angiotensin receptors by RNA extraction from the heart and kidneys of these mice followed by reverse transcriptase (RT)-PCR. B(2)KO mice (HS) were hypertensive after 8 weeks compared with B(2)KO mice on normal diet (HS, 93.4+/-1.5 mmHg, n=7; NS, 61.4+/-2.7 mmHg, n=7). In the HS group, the mean arterial blood pressure was significantly reduced by BQ-123 (5 mg/kg) to 61.9+/-1.8 mmHg (n=7), by BQ-788 (1 mg/kg) to 58.8+/-2.6 mmHg (n=6), by losartan (10 mg/kg) to 73.2+/-1.7 mmHg (n=8) and by captopril (3 mg/kg) to 86.0+/-2.3 mmHg (n=8). The expression studied by RT-PCR did not show any difference (either in precursors or receptors expression) between hypertensive and normal mice. The four antagonists used seemed to reverse the hypertension. These results suggest that ET-1 and angiotensin-II are probably involved in the mechanism that leads to hypertension since the effect of these hormones is probably not compensated by kinins in B(2)KO mice. Further studies are necessary to understand the implication of the cross-talk between these hormones in the hypertensive state.

Asunto(s)

Antagonistas de los Receptores de Endotelina , Hipertensión/tratamiento farmacológico , Oligopéptidos/uso terapéutico , Péptidos Cíclicos/uso terapéutico , Piperidinas/uso terapéutico , Angiotensina II/genética , Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Captopril/farmacología , Endotelina-1/genética , Endotelinas/genética , Femenino , Hipertensión/metabolismo , Riñón/metabolismo , Losartán/farmacología , Masculino , Ratones , Ratones Noqueados , Miocardio/metabolismo , Precursores de Proteínas/genética , ARN Mensajero/análisis , Receptor de Bradiquinina B2 , Receptor de Endotelina A , Receptor de Endotelina B , Receptores de Angiotensina/genética , Receptores de Bradiquinina/genética , Receptores de Bradiquinina/metabolismo , Receptores de Endotelina/genética , Receptores de Endotelina/metabolismo , Cloruro de Sodio Dietético/administración & dosificación